RXi Pharmaceuticals (RXII) Data to Be Presented at Conference Today
More News related to RXII
- RedChip Announces Its Small-Cap Equities Virtual Conference, December 1, 2009
- CytRx Announces Plan to Initiate a Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Soft Tissue Sarcomas
- RXi Pharmaceuticals Wins 2009 RNAi Technology Innovation of the Year Award from Frost & Sullivan
- CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer
- RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2009
After the close, RXi Pharmaceuticals Corporation (Nasdaq: RXII) announced that Dmitry Samarsky, Ph.D., Vice President of Technology Development, will be presenting at the Discovery on Target scientific conference in Boston, MA today, November 4, 2009.
The presentation will describe RXi’s therapeutic platform, including RXi’s next generation rxRNA™ compounds and advanced delivery approaches. The talk will focus on self-delivering rxRNA (sd-rxRNA™) compounds. Dr. Samarsky will present data exemplifying the robust performance of RXi’s self-delivering rxRNAs across multiple genes, cell types, target tissues and animal species.
Related Categories
FDAStocks Mentioned
-0.11Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Stock movement
Rita Denowitz on Nov 4, 2009 09:50 AMWill good news drive the stock down once again? Who is driving the train?